J&J has arguably the best record of any major U.S. company in steadily growing its revenue, net income and dividends over many years. The stock yields 3.1% now, while the shares, in the low 60s, are off the high of 70 hit in 2008. Dividend growth over the past five years averaged 12%, which means return on equity is 25%-plus. J&J has been trading at less than 13 times analysts' consensus 2010 earnings estimates of $4.93 a share. Pioneer Investment's Carey says that multiple is below both the company's historical average of 17 and the overall market. "You just don't see that kind of discount. Here you have a chance to buy it at a cheap price," he says.

growth dividend

That means the ability to buy so many companies that are overseas-oriented: Intel (INTC), Microsoft (MSFT), Cisco (CSCO), Johnson & Johnson (JNJ), Caterpillar (CAT), 3M (MMM), United Tech (UTX), Boeing (BA), Hewlett-Packard (HPQ), McDonald's (MCD), Alcoa (AA), IBM (IBM), Procter (PG), Coke (KO), Merck (MRK) and Pfizer (PFE), just to give you the Dow stocks that are weighted perfectly for the overseas turn.

Solid performer, Dividends

On "Mad Money" on Oct. 15, Cramer said he'd been excited by J&J's earnings beat at first but had decided to put the stock in his Sell Block because the earnings were due to lowered R&D spending and a favorable tax rate. "That's not how we want to see companies make their numbers," he said.

Not a fast moving company but very solid and low risk, a good longterm investment that will pay rewards soon. Also right at the right price, buy now at 59 and you will get more $$$

Rating = B

What sectors might benefit from boomer consumers' continued strength? If The Graduate were made today, says Martin, "the cocktail party advice on the coming industry would shift from 'plastics' to 'probiotics.' Go into the aging businesses, all of which will thrive with longer life expectancies as the boomers age." Along with pharmaceuticals and other health-related goods and services, beauty products should do well. Procter & Gamble 's (PG) Olay, L'Oréal (LRLCY) and its Garnier unit and Johnson & Johnson 's (JNJ) Neutrogena have all launched products targeted to boomer women.

Johnson & Johnson (JNJ) is stalled, so is Pfizer (PFE). Same with Kraft (KFT).

"Johnson & Johnson (JNJ) has purchased 14.6 million shares of Dutch biotech company Crucell (CRXL) for 301.8 million euros ($441 million)." Read more here.

everybody will need toiletries.

I can never seem to play this stock right.

They seem over rated and you con only make pennies on the stock.

it's $2 below where I bought it 8 years ago

doesn't move much

Same reason as above. Never made any gains on this stock.

It's a quality stock that is motionless.

Watching this one

johnson n john

long time jets fan and the cuirse will carry over to the stock!!!

The best stock in the world has already come ripe.